From PsychonautWiki
(Redirected from AMT)
Jump to: navigation, search
Summary sheet: ΑMT
Molecular structure of αMT
Chemical Nomenclature
Common names AMT, αMT, Indopan
Substitutive name α-Methyltryptamine, alpha-methyltryptamine
Systematic name 2-(1H-indol-3-yl)-1-methyl-ethylamine
Class Membership
Psychoactive class Entactogen / Psychedelic
Chemical class Tryptamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 5 - 10 mg
Light 10 - 25 mg
Common 25 - 40 mg
Strong 40 - 60 mg
Heavy 60 - 80 mg
Total 13 - 15 hours
Onset 60 - 180 minutes
Peak 4 - 6 hours
After effects 1 - 5 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

α-Methyltryptamine (also known as αMT, AMT, aMT, and Indopan) is a synthetic entactogenic substance of the tryptamine chemical class that produces long lived entactogenic, stimulant and psychedelic effects when administered.[1] It was originally developed as an antidepressant by workers at a Michigan pharmaceutical manufacturing company known as Upjohn in the 1960s.[2]

In the 1960s αMT was prescribed in 5 - 10 milligram doses as an antidepressant in the Soviet Union under the trade name Indopan.[3]

Erowid has received "a handful of unverifiable reports of hospitalization after high-dose (over 60 mg oral) αMT ingestion."[4] There were 22 deaths linked to αMT in England and Wales where the drug became popular as a legal high from 2012 until it was banned in early 2015.[5]. One widely reported fatality involved an 18 year old male who was believed to have taken just under a gram - a large overdose.[6] There is also an earlier reported death from αMT which was reported in February 2003 by the Miami-Dade County Medical Examiner Department, but it is unknown how much was taken.[7]


αMT, or α-Methyltryptamine is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. AMT is substituted at the alpha carbon Rα of its tryptamine backbone with a methyl group.

AMT is found in freebase form as a racemate of its (R-) and (S-) enantiomers.[8]


Further information: Serotonergic psychedelic

αMT's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist.

αMT also acts as a releasing agent of serotonin, noradrenaline, and dopamine.[9][10] It also acts as a very weak, non-selective RIMA in-vitro[11] and in-vivo.[12], but this is unlikely to be very significant (if at all) with common doses.

However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include injury or death.

Physical effects

Visual effects

Cognitive effects

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential


This toxicity and harm potential section is a stub.

As such, it may contain incomplete or even dangerously wrong information. You can help by expanding upon or correcting it.
We also recommend that you practice diligent independent research and the most thorough harm reduction practices when using this substance.

As a powerful monoamine reuptake inhibitor, αMT can be dangerous when taken in excessive doses or when combined with substances such as MAOIs, RIMAs, stimulants and any substance which act as a releasing agent or reuptake inhibitor of serotonin and dopamine. There is one reported death from AMT, but it is not known how much of the substance was taken.[7] Erowid states that they have received "a handful of unverifiable reports of hospitalization after high-dose (over 60 mg oral) AMT ingestion."[4]

The toxicity and long-term health effects of recreational αMT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because AMT is a research chemical with very little history of human usage. Anecdotal evidence from people who have tried AMT within the psychedelic community suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is worth noting that αMT's analogue αET has been shown to produce long-lasting serotonergic neurotoxicity at very high doses.[13] It is possible that AMT could cause the same neurotoxicity at high dosages or with repeated long-term use.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

AMT is moderately habit-forming.

Tolerance to the effects of αMT are built almost immediately after ingestion. After that, it takes about 14 days for the tolerance to be reduced to half and 1 month to be back at baseline (in the absence of further consumption). AMT presents cross-tolerance with all psychedelics, meaning that after the consumption of αMT all psychedelics will have a reduced effect.

Dangerous interactions

Deaths from αMT are rare[4][7] but, as a powerful monoamine reuptake inhibitor (MRI), injury could occur when excessive doses are taken or when it is taken with substances such as MAOIs, RIMAs, stimulants and any substance which act as a releasing agent or reuptake inhibitor of neurotransmitters such as serotonin and dopamine.[14]



This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Australia: Sale and possession of AMT is illegal.[citation needed]
  • Canada: Canada has no mention of this substance in the Controlled substances and Substances Act.[15]
  • Germany: Sale and possession of AMT is illegal.[citation needed]
  • Greece: Sale and possession of AMT is illegal.[citation needed]
  • Japan: Sale and possession of AMT is illegal.[citation needed]
  • Latvia: AMT is a Schedule I drug.[16]
  • Russia: Sale and possession of AMT is illegal.[citation needed]
  • Sweden: Sale and possession of AMT is illegal.[17]
  • United Kingdom: AMT is a Class A drug in the United Kingdom as a result of the tryptamine catch-all clause.[18]
  • United States: AMT is a Schedule I drug.[19]

See also

External links


  1. Erowid Online Books : TIHKAL - #48 a-MT | http://www.erowid.org/library/books_online/tihkal/tihkal48.shtml
  2. US Patent 3296072 - Method of Treating Mental Depression
  3. AMT's TiHKAL entry by Alexander Shulgin (IsomerDesigns) https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=48
  4. 4.0 4.1 4.2 AMT (Alphamethyltryptamine, IT-290) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/amt/amt_death.shtml
  5. Deaths Related to Drug Poisoning, England and Wales, 2016 release (table 8) | https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathsrelatedtodrugpoisoningenglandandwalesreferencetable
  6. Call to ban legal high drug AMT, The Telegraph, 10th June 2014 | http://www.telegraph.co.uk/news/uknews/law-and-order/10890567/Call-to-ban-legal-high-drug-AMT.html
  7. 7.0 7.1 7.2 Boland DM, Andollo W, Hime GW, Hearn WL. “Fatality due to acute alpha-methyltryptamine intoxication”. J Anal Toxicol. 2005 Jul-Aug;29(5):394-7. | https://www.erowid.org/references/refs_view.php?ID=6603
  8. http://isomerdesign.com/PiHKAL/read.php?id=48
  9. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain | http://linkinghub.elsevier.com/retrieve/pii/S0014-2999(06)01381-1
  10. In vitro screening of psychoactive drugs by [(35)S]GTPgammaS binding in rat brain membranes | https://www.jstage.jst.go.jp/article/bpb/30/12/30_12_2328/_article
  11. Studies of Monoamine Oxidase and Semicarbazide-Sensitive Amine Oxidase II. Inhibition by α-Methylated Substrate-Analogue Monoamines, α-Methyltryptamine, α-Methylbenzylamine and Two Enantiomers of α-Methylbenzylamine | https://www.jstage.jst.go.jp/article/jphs1951/41/2/41_2_191/_article
  12. THE EFFECT OF THREE TRYPTAMINE DERIVATIVES ON SEROTONIN METABOLISM IN VITRO AND IN VIVO | http://jpet.aspetjournals.org/content/127/2/110.short
  13. Reduction in brain serotonin markers by α-ethyltryptamine (Monase) (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/001429999190686K
  14. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity | http://bja.oxfordjournals.org/content/95/4/434
  15. CSDA | http://isomerdesign.com/Cdsa/schedule.php?structure=C
  16. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (Triptamīni) | http://likumi.lv/doc.php?id=121086
  17. Svensk författningssamling Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor | http://www.notisum.se/rnp/sls/sfs/20050026.pdf
  18. Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I#reference-M_F_c7632653-ddad-4420-f307-e3da1e36d30e
  19. Drug Enforcement Administration | http://webcache.googleusercontent.com/search?q=cache:http://www.deadiversion.usdoj.gov/drug_chem_info/amt.pdf